Lineage Cell Therapeutics, Inc.

DB:BT3 Stock Report

Market Cap: €147.7m

Lineage Cell Therapeutics Future Growth

Future criteria checks 2/6

Lineage Cell Therapeutics is forecast to grow earnings and revenue by 50.3% and 63.5% per annum respectively while EPS is expected to grow by 51.1% per annum.

Key information

50.3%

Earnings growth rate

51.1%

EPS growth rate

Biotechs earnings growth34.9%
Revenue growth rate63.5%
Future return on equityn/a
Analyst coverage

Good

Last updated20 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:BT3 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202616-34-36N/A6
12/31/20258-26-30N/A7
12/31/20245-28-2336
6/30/20246-24-22-22N/A
3/31/20248-24-24-23N/A
12/31/20239-21-29-29N/A
9/30/20239-23-31-31N/A
6/30/202311-22-32-31N/A
3/31/202312-24-33-32N/A
12/31/202215-2611N/A
9/30/202214-4933N/A
6/30/202213-5144N/A
3/31/20229-4956N/A
12/31/20214-43-24-24N/A
9/30/20214-12-24-23N/A
6/30/20212-12-24-23N/A
3/31/20212-14-22-22N/A
12/31/20202-21-20-20N/A
9/30/20203-27-20-20N/A
6/30/20203-36-22-22N/A
3/31/20203-59-28-28N/A
12/31/20194-12-32-32N/A
9/30/20193-52-34-32N/A
6/30/2019331-35-32N/A
3/31/2019557-32-30N/A
12/31/20185-46-34-31N/A
9/30/20185-73-33-31N/A
6/30/20186-125-33-31N/A
3/31/20184-133N/A-33N/A
12/31/20173-20N/A-31N/A
9/30/2017447N/A-34N/A
6/30/2017364N/A-35N/A
3/31/20174100N/A-36N/A
12/31/2016634N/A-42N/A
9/30/2016625N/A-47N/A
6/30/20167-20N/A-50N/A
3/31/20168-54N/A-50N/A
12/31/20157-47N/A-45N/A
9/30/20157-45N/A-40N/A
6/30/20156-39N/A-37N/A
3/31/20155-39N/A-38N/A
12/31/20145-36N/A-39N/A
9/30/20145-45N/A-38N/A
6/30/20145-46N/A-36N/A
3/31/20145-44N/A-33N/A
12/31/20134-44N/A-30N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BT3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BT3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BT3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BT3's revenue (63.5% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: BT3's revenue (63.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BT3's Return on Equity is forecast to be high in 3 years time


Discover growth companies